Clinical Trial Update: Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating intraprostatic botulinum toxin A for benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Enlargement
• Benign Prostatic Hyperplasia

Drugs mentioned

• Botulinum toxin type A (botulinum toxin type A)

Snippet

Sponsor: Catholic University of the Sacred Heart | Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Enlargement (BPE) | Phase 2, Phase 3 | Status: COMPLETED